Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
HyperCVAD Chemotherapy for MCL in the Plerixafor Era
Biol Blood Marrow Transplant; ePub 2017 Apr 18; Salhotra, et al
Plerixafor did not ameliorate the effects rituximab-hyperCVAD (R-hyperCVAD) had on peripheral blood stem cell mobilization in a study involving 181 individuals with mantle cell lymphoma (MCL).
Participants were treated with either R-hyperCVAD or less intense R-bendamustine and R-CHOP only between 2005 and 2015. Investigators looked at therapy impact on collection of hematopoietic cell progenitors before autologous stem cell transplant (ASCT). Among the results:
- In the post-plerixafor era (after mid-2009), hematopoietic progenitor cell collection failure rate with R-hyperCVAD was 17%; it was 4% in the other group.
- These rates had been similar in the pre-plerixafor era.
- Among patients who received less intensive chemotherapy, mobilization failure rate declined to 4% in the post plerixafor era, vs 11% beforehand.
- Mobilization failure rate increased in the R-hyperCVAD group during this time to 17% from 12%.
Salhotra A, Shan Y, Tsai N, et al. HyperCVAD chemotherapy in mantle cell lymphoma patients is associated with higher rates of hematopoietic progenitor cell mobilization failure, despite plerixafor rescue. [Published online ahead of print April 18, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.04.011.